"Company") today announced measurable progress in the
development of a new procedure for the
selective extraction of male DNA from mixtures of male and
female cells. The project's goal is to
improve the processing of sexual assault evidence kits
(also called "rape kits"); the new procedure is
based on the Company's patented Pressure Cycling Technology
("PCT"). The data were reported at the
recent 17th Latin-American Symposium on Biotechnology,
Biomedical, Biopharmaceutical, and Industrial
Applications of Capillary Electrophoresis and Microchip
Technology ("LACE 2011"). This international
conference was held from December 2-6, 2011 in Hollywood,
Florida.
Dr. Bruce R. McCord, Associate Director of the
International Forensic Research Institute (IFRI),
Department of Chemistry and Biochemistry, Florida
International University (FIU), and Ms. Deepthi
Nori, MFS from the IFRI - FIU, presented the study, which
was entitled Application of Pressure Cycling
Technology (PCT) in Differential Extraction. Dr. McCord and
Ms. Nori are working on the development
of a unique, PCT-based method to differentially extract DNA
from sperm and vaginal epithelial cells in
the same mixture. Dr. McCord and Ms. Nori believe that this
novel method has the potential to
significantly decrease rape kit processing time, increase
throughput, decrease costs, and improve results.
They also believe that it may lead to better identification
of criminals involved in sexual assaults, by
helping to confirm suspect and victim contact.
the selective extraction of male DNA from sperm cells in
the presence of much larger quantities of female
DNA. This is accomplished by first separating the sperm and
non-sperm fractions. This processing step
is essential, yet it remains difficult, complex,
time-consuming, and not aligned with automation. It is
truly a serious bottleneck in sexual assault casework."
kits nationwide, and an estimated 180,000 new sexual
assault cases each year, it is essential that improved
methods for processing rape kits be developed. We believe
that the data reported by Dr. McCord and Ms.
Nori indicate that PCT can potentially increase the
recovery of DNA from sperm cells, without the need
for a long and laborious separation step. Based on their
findings, we believe their unique PCT-based
method could result in better quality of results and
significantly increased throughput, which in turn could
result in a reduction in the rape kit backlog and an
increase in arrest rates for sex crimes. And for PBI
shareholders, we believe this method could result in
significant increases in Barocycler instrument
placements and product revenue in 2012 and beyond."
Dr. Bruce McCord said: "Our goal is to develop a PCT-based
method that can selectively disrupt sperm
cells in mixtures containing female cells, without the need
to first separate the cells. At the LACE 2011
Meeting, we reported on the successful completion of this
important processing step in laboratory
samples. We have now begun to test this unique approach in
complex mixtures and real sexual assault
evidence kit samples. We expect to report on these new
studies at the annual American Academy of
Forensics Sciences ("AAFS") Conference in February, and at
other venues throughout the year."
About Pressure BioSciences
Pressure BioSciences, Inc. ("PBI") (NASDAQ: PBIO) is
focused on the development, marketing, and sale of
proprietary laboratory instrumentation and associated
consumables based on Pressure Cycling Technology ("PCT").
PCT is a patented, enabling technology platform with
multiple applications in the estimated $6 billion life
sciences sample preparation market. PCT uses cycles of
hydrostatic pressure between ambient and ultra-high levels
to control bio-molecular interactions. PBI currently
focuses its efforts on the development and sale of
PCT-enhanced sample preparation systems (instruments and
consumables) for mass spectrometry, biomarker discovery,
bio-therapeutics characterization, vaccine development,
soil and plant biology, forensics, histology, and
counter-bioterror applications.
Forward-Looking Statements
Statements contained in this press release regarding the
Company's intentions, hopes, beliefs,
expectations, or predictions of the future are
"forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements
regarding the expected advantages of PBI's PCT product line
in processing rape kit samples; the potential
for PCT as a tool for the differential extraction of DNA
from sperm cells and epithelial cells, without the
need for prior separation; that the PCT method has the
potential to significantly decrease rape kit
processing time, increase throughput, decrease costs,
improve results, lead to better identification of
criminals involved in sexual assaults, confirm suspect and
victim contact, and help prove innocence; that
the PCT method could result in an increase in product sales
in 2012 and beyond; and the number of
unprocessed rape kits and the number of new sexual assault
cases each year. These statements are based
upon PBI's current expectations, forecasts, and assumptions
that are subject to risks, uncertainties, and
other factors that could cause actual outcomes and results
to differ materially from those indicated by
these forward-looking statements. These risks,
uncertainties, and other factors include, but are not
limited
to: unforeseen technological difficulties or business
issues in the implementation of the PCT method in
the processing of rape kits that may impede or prevent the
achievement of the expected advantages of the
PCT method for such processing; due to unforeseen technical
difficulties, or marketing, sales, and
distribution difficulties, the PCT method may not be
adopted by the forensics community as an accepted
workflow for rape kit sample preparation or the forensics
community may not perceive the benefits of
PCT for sample preparation; if actual operating costs are
higher than anticipated, or revenues from
product sales are less than anticipated, the Company may
need additional capital prior to March 2012; and
if the Company fails to achieve its plan to regain
compliance with the NASDAQ Listing Rules for
minimum stockholders' equity and the minimum bid price of
$1.00 per share, the Company's common
stock will be delisted from The NASDAQ Capital Market.
Additional risks and uncertainties that could
cause actual results to differ materially from those
indicated by these forward-looking statements are
discussed under the heading "Risk Factors" in the Company's
Annual Report on Form 10-K for the year
ended December 31, 2010, as amended, and other reports
filed by the Company from time to time with
the SEC. The Company undertakes no obligation to update any
of the information included in this release,
except as otherwise required by law.
PBI filed a registration statement (including a prospectus)
with the SEC for the offering to which this
communication may relate. Before you invest, you should
read the prospectus in that registration
statement for the offering and other documents PBI has
filed with the SEC for more complete information
about PBI and the offering. You may get these documents for
free by visiting EDGAR on the SEC Web
site at www.sec.gov.
request.
http://www.pressurebiosciences.com
distribué par | Ce noodl a été diffusé par Pressure BioSciences Inc. et initialement mise en ligne sur le site http://www.pressurebiosciences.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 15:55:51 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |